RECEIVED CENTRAL FAX CENTER

MAY 2 1 2007

2

Docket No. GJE-7477 Serial No. 10/517,882

## In the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Canceled).

2 (Currently amended). A composition comprising (+)-nefopam, wherein said composition is an aqueous solution, wherein said composition has a pH in the range of 4 to 7 and wherein said composition is suitable for intranasal administration, and wherein said composition further comprises a mucoadhesive agent.

3 (Currently amended). The composition, according to claim 2, which further comprises one or more of a mucoadhesive agent, a solubility enhancer, a humectant, and a buffer.

4 (Previously presented). A method for treating pain wherein said method comprises intranasal administration, to an individual in need of such treatment, of an aqueous solution comprising (4)-nefopam, wherein said aqueous solution has a pH in the range of 4 to 7.

5 (Previously presented). The method, according to claim 4, wherein said aqueous solution further comprises one or more of a mucoadhesive agent, a solubility enhancer, a humectant, and a buffer.

6 (Previously presented). The method, according to claim 4, further comprising use of one or more of the following: baclofen, gabapentin, acetaminophen, a non-steroidal anti-inflammatory drug, a narcotic analgesic, a local anesthetic, an NMDA antagonist, a neuroleptic agent, an anti-convulsant, an anti-spasmodic, an anti-depressant, or a muscle relaxant.

JAGJEA7477\PTO\AmenJ-F.doc\DNII/Ia

3

Docket No. GJE-7477 Serial No. 10/517,882

7 (Previously presented). The composition, according to claim 2, wherein said composition has a pH in the range of 5.5-6.5.

8 (Previously presented). The method, according to claim 4, used to treat pain associated with cancer.

9 (Currently amended). The method, according to claim 4, wherein [[the]]a daily dose of (+)-nefopam is administered to an individual and the daily dose is less than 60 mg.